501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Makes Advances with Marijuana Breathalyzer Development
and THC Breath Capture
The Cannabix Marijuana Breathalyzer is being developed to
provide
law enforcement and employers a tool to enforce public
safety.
Vancouver, British
Columbia -- July
15, 2019
--
InvestorsHub NewsWire -- Cannabix
Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or
Cannabix") developer of the
Cannabix Marijuana Breathalyzer for law enforcement and the
workplace, is pleased to report that Company
scientists
have
made significant
advancements with
analyte in breath capture and FAIMS cell development.
Cannabix scientist
having been optimizing the breath / sample capture procedures and
technology to maximize ?9-tetrahydrocannabinol
("THC")
analyte
capture from human breath. THC is found in breath in generally low
quantities. The Company has significantly improved sample
collection methods using the breath collection
unit ("BCU") and other newly
developed techniques. In addition, engineers have developed a
proprietary next generation FAIMS cell that is currently being
tested. The Company has
been steadily progressing with human breath testing at its
Vancouver, BC, based lab with its FAIMS (field asymmetric
waveform ion mobility spectrometry) THC detection
device and BCU.
Comment
on Saliva Testing
"We
would like to make it clear that roadside saliva tests are
not "breathalyzers"
and do
not represent the promise of breath testing for roadside
marijuana
impairment.
It is
apparent that existing
saliva-testing
devices
are
being used in some jurisdictions because no
regulatory
evidential breath
testing devices
currently exist on
the market.
Cannabix
and our product development work
is
dedicated to the development
of marijuana
breathalyzer technologies.
Saliva testing, also known
as "oral
swab testing"
is not
new technology and has been available for many
years.
There are well
documented
issues
with saliva testing including its
ability
to effectively identify impaired
individuals and
operate
in cold
weather conditions,
to name
a few.
There
are a growing number of
examples of the
lack of confidence in saliva testing devices. In 2018,
Vermont
Senate Judiciary
Committee rejected a bill authorizing the use of
saliva
testing in
traffic enforcement,
amid concerns of
scientific validity, accuracy, and infringement on civil
liberties. In 2019, a Nova Scotia woman
initiated the first
court challenge in Canada related to saliva testing,
where she claims she tested positive for THC,
several hours after she used medical
marijuana. Most police detachments
have not
adopted saliva testing to date, opting
for better technology options that are being developed.
Cannabix believes
that an accurate evidential breath
testing device for THC is the future for law
enforcement and workplace testing, as it is less invasive and will
look to provide superior method to better determine
impairment. It is well documented that
breath is a
better indicator of impairment than saliva, blood, or urine because THC only remains
in breath for short period of time
(2-3
hours) before becoming
virtually undetectable, whereas it can
remain in other body fluids for many hours, days, or even weeks
after smoking. This short time
period of
detection
in breath aligns
with the peak impairment window.
"
technology.
marijuana
breathalyzerits
Cannabix is a well
funded Canadian company that is rapidly developing
.As
the issue of drugged driving becomes increasingly acute, Cannabix
is committed to using its technology, R&D and scientific
experience to provide effective tools to aid law enforcement and
help governments and the public transition to marijuana
legalization in various jurisdictions
and
elsewhere., Canada
companies in the
U.S. and
The
Company has received significant interest for its technology from
police
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage,
days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment
by THC
can be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.